Understand the source comparison
KPV for IBS: Oral vs Subcutaneous Administration
Subcutaneous 500–1000 mcg/day ~95% (near-complete absorption) 10–14 days Moderate (requires reconstitution, daily injection) Severe mucosal inflammation, patients who failed oral therapy Best for inflammation-driven IBS-D with documented gut inflammation (elev
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous
- 500–1000 mcg/day
- ~95% (near-complete absorption)
- 10–14 days
- Moderate (requires reconstitution, daily injection)
- Severe mucosal inflammation, patients who failed oral therapy
- Best for inflammation-driven IBS-D with documented gut inflammation (elevated calprotectin, endoscopic findings). Delivers systemic exposure and faster symptom relief
- Oral (enteric-coated)
- 2000–4000 mcg/day
- 15–25% (first-pass metabolism reduces absorption)
- 3–4 weeks
- Low (capsule form, no preparation)
- Mild-to-moderate IBS symptoms, localized gut inflammation
- Preferred for patients seeking convenience and those with primarily intestinal symptoms. Lower bioavailability offset by direct gut exposure
- Oral (uncoated)
- Not recommended
- <10% (stomach acid degrades peptide)
- Variable/unreliable
- Low
- None
- Avoid. Uncoated oral KPV loses 80–90% potency before reaching the intestine; enteric coating is non-negotiable for oral efficacy